Navigation Links
First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes

-- Additional Findings Reported on Glucose Homeostasis Effects in Normal and Diabetic Rats --

CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- In a 14-day, Phase IIa study of the safety profile of multiple doses of the investigational compound dapagliflozin, a selective inhibitor of the Sodium-Glucose Transporter 2 (SGLT2) administered alone or concomitantly with metformin in subjects with Type 2 diabetes, no discontinuations due to adverse events and no serious adverse events were reported. The study, presented this week at the annual meeting of the American Diabetes Association, also reported that dapagliflozin, in development by Bristol-Myers Squibb Company and AstraZeneca , statistically significantly reduced fasting serum glucose (FSG) and post challenge glucose excursion in subjects with Type 2 diabetes.

The data were from a double-blind, placebo-controlled, randomized, parallel-group study of 47 subjects with an established diagnosis of Type 2 diabetes (ages 18-77) who were either drug-naive or on a stable dose of metformin for at least 4 weeks prior to randomization with hemoglobin A1C levels between 6 and 10 percent with a FSG of less than or equal to 240 mg/dL. Subjects were randomized to receive either placebo (n=8) or dapagliflozin 5 mg (n=11), 25 mg (n=12), or 100 mg (n=16) once daily for 14 days in addition to their stable metformin dose and/or diet alone in an in-patient clinical research unit. The primary endpoint of the study was to assess both the safety and tolerability profiles of multiple doses of dapagliflozin in subjects with Type 2 diabetes. The secondary endpoints of the study included assessing the fasting serum glucose and post challenge glucose excursion. The presentation, "Dapagliflozin, a Selective Inhibitor of the Sodium-Glucose Uptake Transporter 2 (SGLT2), Reduces Fasting Serum Glucose and Glucose Excursion in Type 2 Diabetes Mellitus Patients Over 14 Days", was presented by Bernard Komoroski, PharmD, Ph.D., Senior Research
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
9. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
Post Your Comments:
(Date:7/1/2015)...   Continental Clinical Solutions (Continental) announced it is expanding its Baltimore ... volume in clinical studies and demand for unique patient populations.  ... ... ... ...
(Date:7/1/2015)... , July 1, 2015 OncoSec Medical Inc. ... cancer immunotherapies, today announced that CEO and President Punit ... of the Company,s listing to The Nasdaq Stock Market at ... MarketSite in New York City .   ... investors, and stakeholders, we are honored to open the Nasdaq ...
(Date:7/1/2015)... 2015 The global mHealth ... USD 49,119.2 million by 2020, according to a new ... expected to remain the dominant and fastest growing market ... 2012, and an estimated CAGR of 49.7% from 2014 ... , Browse full research report with TOC ...
Breaking Medicine Technology:Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 2Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 3Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 4OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 2OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5
... Reportlinker.com announces that a new market ... Fetal Monitoring, Diagnostics and ... An overview of the ... tests. Analysis of market trends, with data ...
... -- Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the ... Traditional Chinese Medicine ("TCM") consumer products, today announced that ... conference call on Monday, May 16, 2011 at 8:00 ... the public pre-market on Monday, May 16, 2011. ...
Cached Medicine Technology:Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 2Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 3Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 4Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 5Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 6Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 7Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 8Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 9Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 10Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 11Nutrastar Provides First Quarter 2011 Financial Results Release Date and Conference Call Details 2Nutrastar Provides First Quarter 2011 Financial Results Release Date and Conference Call Details 3
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Summer recess ... with teenagers to fix noses and chins with plastic surgery when they’re looking for ... (ASPS) more than 236,000 cosmetic procedures were performed on patients ages 19 and younger ...
(Date:7/1/2015)... Humble, TX (PRWEB) , ... July 01, 2015 , ... ... also another symptom found in a significant number of women: leg pain. Northeast Houston ... , Leg pain, a symptom of venous reflux disease, is underdiagnosed and often ...
(Date:7/1/2015)... ... July 01, 2015 , ... Scoliosis is a disorder in which the normally straight vertical line ... 2 to 3 percent of the population, or an estimated 6 to 9 million people. ... between the ages of 10 and 15. Most types of scoliosis are more common in ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... big summer sale. Customers purchasing two or more Bunion Booties directly from ... , Bunion Bootie temporarily corrects misaligned toes and its ultra thin properties ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... leadership solutions firm B. E. Smith, Tri-City Medical Center in Oceanside, ... with a proven record of leading organization-wide compliance adaptation efforts and growing a ...
Breaking Medicine News(10 mins):Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 2Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 3Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2Health News:Tri-City Medical Center Hires New Chief Compliance Officer 2Health News:Tri-City Medical Center Hires New Chief Compliance Officer 3
... , ... Birmingham, AL (PRWEB) August 3, 2008 -- The ... Tolbert took home two awards in the 12th Annual "Best in ... was announced as the winner in the category of Best Company: ...
... A NATIONAL AIDS STRATEGY, WASHINGTON, Aug. 2 ... anticipated revised estimate of,annual new cases of HIV infections ... 6, 2008 issue of the Journal of the American ... suggests,that the HIV epidemic here in the United States ...
... Affected by Dangerous Tysabri Effects. , ... Houston, TX ... Middleman announce the launch of a http://www.tysabrilawsuitattorney.com [website] dedicated ... result of taking Tysabri (natalizumab)., , ,Tysabri, a drug used to ...
... federal Centers for,Disease Control and Prevention,s (CDC) long anticipated ... be revealed on Aug. 3 in a paper,published in ... estimated number of new infections suggests that the HIV ... current statistics portray.,The revised estimate for 2006 will replace ...
... multiforme (GBM), one of the most aggressive types of ... studies indicated therapeutics inhibiting a group of proteins known ... to individuals with GBM, these RTK inhibitors have met ... of patients respond to such treatment and most subsequently ...
... or work" as the main reason they changed mammography ... at the University of Cincinnati Medical Center and The ... included 303 current mammography patients ("stayers") and 117 patients ... ("leavers"), said Mary C. Mahoney, MD, lead author of ...
Cached Medicine News:Health News:Air Ambulance Company AirMed International Wins Multiple "Best in Business" Awards from Birmingham Business Journal 2Health News:Estimate of Annual HIV Incidence Increases to 56,300 2Health News:Tysabri Lawyers Pulaski & Middleman Launch Web Resource Center for Patients Suffering from Tysabri Side Effects 2Health News:Estimate of Annual HIV Incidence Increases Significantly; New Estimate Will Show Need For a National AIDS Strategy 2Health News:Estimate of Annual HIV Incidence Increases Significantly; New Estimate Will Show Need For a National AIDS Strategy 3
... The ABL800 FLEX is a fully ... most advanced blood gas analyzer along ... gives you the freedom to focus ... FLEX provides features that are essential ...
Flatbed Agitator....
Flatbed Agitator....
... platelet agitators offer a wide range of ... the drawer storage platform to agitate smoothly, ... wear down and squeak. Sturdy, one-piece perforated ... air circulation for your platelets., ,i.Series platelet ...
Medicine Products: